Work

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

Year: 2016

Type: article

Study design: Clinical Trial

Source: Journal of Neuro-Oncology

DOI: 10.1007/s11060-016-2094-0

Authors: Mustafa Khasraw, Adrian Lee, Sally McCowatt, Zoltan Kerestes, Marc E. Buyse, Michael Back, Ganessan Kichenadasse, Stephen Ackland, Helen Wheeler

Institutions: The University of Sydney, Royal North Shore Hospital, National Health and Medical Research Council, International Drug Development Institute (Belgium), Flinders University, Flinders Medical Centre, Calvary Mater Newcastle Hospital

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Merck KGaA, EMD Serono

OpenAlex ID: W2289944541

FWCI: 3.776

Cites: 30

Cited by: 52

Related to: 10